Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:zuranolone
|
| gptkbp:approvalYear |
2023
|
| gptkbp:ATCCode |
N06AX34
|
| gptkbp:CASNumber |
2050038-84-9
|
| gptkbp:chemicalFormula |
C22H17F3N2O2S
|
| gptkbp:form |
capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zurzuvae
|
| gptkbp:indication |
postpartum depression
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Biogen
gptkb:Sage_Therapeutics |
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
GABA-A receptor positive allosteric modulator
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
dizziness fatigue urinary tract infection drowsiness |
| gptkbp:status |
FDA approved
|
| gptkbp:treatment |
14 days
|
| gptkbp:bfsParent |
gptkb:Sage_Therapeutics
|
| gptkbp:bfsLayer |
5
|